Blackstone backs Pfizer obesity drug with $1.5B

7 sourcesUpdated Nov 12, 20261 min read

0

Blackstone backs Pfizer obesity drug with $1.5B — Photo: Jim.henderson / Wikimedia Commons (CC BY-SA 4.0)

Sponsored

Blackstone Life Sciences and funds managed by its perpetual private equity strategy will provide Pfizer up to $1.5 billion through 2028 to help develop berobenatide, an experimental monthly GLP-1 drug for chronic weight management and obesity-related conditions. In return, Blackstone may receive payments tied to U.S. regulatory approval and commercial sales milestones, but Pfizer retains ownership, operational control and decision-making. Pfizer plans more than 20 trials for obesity and related conditions in 2026, including 10 ongoing or planned Phase 3 trials of berobenatide, which is also being studied for conditions including sleep apnea and knee osteoarthritis. The agreement expands a funding relationship between the companies and gives Pfizer additional resources as it seeks to compete in a market dominated by Eli Lilly and Novo Nordisk.

Sponsored

In this story:

Sponsored

How it spread

Broke stocktitan.net · Nov 11, 4:30 PM ET7 sources +4h on

More on this story

Back to News

Business

Anthropic IPO Valuation Could Reach $1.5 Trillion

Anthropic’s planned IPO is facing mounting uncertainty as investors reportedly push to lower its expected valuation from roughly $1.4 trillion–$1.5 trillion, with estimates ranging toward $1 trillion to $1.3 trillion amid a sell-off in AI stocks. Prediction-market odds for a near-term listing have also fallen, and reports say the company could reduce the offering or delay it.

420 sources

World

Claim check

What each side asserts, disputes — or leaves out entirely.

Analyzing the coverage…

Where do you land?

Whose framing of this story rings truest to you?

Sponsored

Coverage

Sponsored

Comments

Ask Genius by OpenServe:

Free account · your comment posts right after signup

Sponsored

Pope Leo XIV Visits Argentina Amid Milei Tensions

Pope Leo XIV’s visit to Argentina—the first papal visit since 1987—is drawing attention to his ideological divide with President Javier Milei, whose austerity policies the Catholic Church says have harmed the poor. Leo’s first stop at a home for people with disabilities underscores the dispute: the facility says government cuts have halted supplies of medication, special food and diapers.

123 sources

Sponsored

Finance

CoreWeave Raises Outlook as Debt and Spending Mount

CoreWeave’s third-quarter revenue topped expectations, its backlog reached about $133 billion, and the AI cloud provider raised its full-year revenue outlook to $13 billion–$13.3 billion. Shares rose in after-hours trading, though investors remain focused on the company’s debt and rising interest costs as it expands capacity.

155 sources